Kineret market report flags growth from autoimmune and inflammatory disease demand

The Business Research Company says the Kineret market is set to expand through 2026-2035 as autoimmune and inflammatory disease diagnoses rise and biologic use widens. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Rising autoimmune and inflammatory disease rates are expanding demand for Kineret, a biologic used to treat conditions driven by excess inflammation. - The market outlook points to continued growth in rare disease care, pediatric use, and broader adoption of targeted cytokine therapies.

What happened: - The Business Research Company published its Kineret Global Market Report 2026, covering market size, trends, and forecasts for 2026-2035. - The report says the Kineret market is drawing attention as medical advances and greater awareness of inflammatory and autoimmune disorders increase the need for effective treatments. - Kineret is the brand name for anakinra, a prescription medication that blocks interleukin-1, a protein central to inflammation and immune responses. - The report identifies North America as the largest Kineret market in 2025. - The report forecasts Asia-Pacific as the fastest-growing regional market in the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company is offering a free sample of the report and a full report link online. More information - The full report is available here. The full report

The details: - Historical Kineret market growth was driven by unmet need in inflammatory diseases, successful IL-1 blockade outcomes, better diagnosis of rare syndromes, wider hospital use of biologics and long-term safety data. - Future growth is expected from greater recognition of autoinflammatory diseases, expanded Kineret indications, higher biologic use in pediatric patients, improved access to specialized care and continued biologics innovation. - Key trends cited in the report include broader IL-1 inhibitor use, more focus on autoinflammatory conditions, increased pediatric inflammatory disease management, preference for targeted cytokine treatments and rising use in rare inflammatory syndromes. - The report says autoimmune diseases affect about one in 10 people, citing UK National Institute for Health and Care Research data from May 2023. - That NIHR data points to 19 recognized autoimmune conditions affecting 10% of the population, including 13% of women and 7% of men. - Crohn’s and Colitis Canada said in 2023 that inflammatory bowel disease in Canada is rising from 322,600 patients, or 0.8% of the population, in 2023 to an estimated 470,000, or 1.1%, by 2035. - Crohn’s and Colitis Canada also projected new IBD diagnoses will rise from 11,000 in 2023 to 14,000 in 2035. - The report notes Kineret is a recombinant version of the human interleukin-1 receptor antagonist, designed to block IL-1 activity and reduce inflammation.

Between the lines: - The report frames Kineret’s market opportunity around a broader shift toward targeted biologics rather than broad immune suppression. - The emphasis on pediatric use and rare syndromes suggests the addressable market is expanding beyond traditional adult inflammatory disease segments. - North America’s lead and Asia-Pacific’s growth outlook point to a mature core market and a faster-rising international opportunity.

What's next: - The report expects broader use of Kineret and other IL-1 inhibitors as diagnosis rates and specialty care access improve. - Market watchers will likely track whether label expansion and biologic adoption in pediatric care accelerate demand through 2035. - The Business Research Company says its 2026 report package also includes TAM analysis, a company scoring matrix, forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company says additional 2026 report features include market attractiveness scoring, key technology analysis and future trend analysis.

The bottom line: - Kineret’s growth story is tied to rising autoimmune and inflammatory disease prevalence, with the strongest near-term market leadership in North America and the fastest growth expected in Asia-Pacific.